Hologic, Inc. (NASDAQ:HOLX) Given Average Recommendation of “Hold” by Analysts

Shares of Hologic, Inc. (NASDAQ:HOLX) have received an average recommendation of “Hold” from the fifteen ratings firms that are presently covering the company, MarketBeat.com reports. Thirteen equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $78.4167.

Several research firms have recently weighed in on HOLX. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Evercore downgraded shares of Hologic from an “outperform” rating to an “in-line” rating and dropped their target price for the stock from $79.00 to $78.00 in a report on Monday, January 5th. Finally, Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th.

Hologic Stock Up 0.3%

HOLX opened at $75.61 on Tuesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04. The company has a market capitalization of $16.88 billion, a PE ratio of 31.50, a P/E/G ratio of 2.24 and a beta of 0.73. The stock’s fifty day moving average is $75.18 and its 200-day moving average is $73.09. Hologic has a one year low of $51.90 and a one year high of $75.75.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.87 EPS. On average, equities analysts predict that Hologic will post 4.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in HOLX. Invesco Ltd. increased its stake in Hologic by 72.5% in the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after purchasing an additional 3,505,828 shares in the last quarter. Becker Capital Management Inc. raised its holdings in Hologic by 20.0% during the 3rd quarter. Becker Capital Management Inc. now owns 81,755 shares of the medical equipment provider’s stock worth $5,518,000 after buying an additional 13,610 shares during the period. Natixis Advisors LLC lifted its stake in Hologic by 23.4% during the third quarter. Natixis Advisors LLC now owns 437,338 shares of the medical equipment provider’s stock valued at $29,516,000 after buying an additional 82,894 shares in the last quarter. Illinois Municipal Retirement Fund lifted its stake in Hologic by 20.4% during the third quarter. Illinois Municipal Retirement Fund now owns 172,294 shares of the medical equipment provider’s stock valued at $11,628,000 after buying an additional 29,143 shares in the last quarter. Finally, Readystate Asset Management LP acquired a new position in shares of Hologic in the third quarter worth about $4,161,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.